dataesr/scientific-paragraphs-categorization huggingface dataset:
03). Finally, a series of primary diffuse pleural mesotheliomas including the epithelioid (n = 148), biphasic (n = 15), and sarcomatoid (n = 12) histological types was recently evaluated using the E1LN3 antibody for cancer stem cell markers and for PD-L1. 21 Overall, 33% of analyzed tumors (57/175) contained PD-L1-positive cells (membranous or cytoplasmic staining with a 5% cutoff), resulting in a decreased OS in the 66 patients with available survival data (median OS: 6. 0 months vs 18. 0 months for patients with PD-L1negative tumors, p < 0. 01).
Final results from a U. S. Phase-2 single-arm trial assessing the activity of fixed-dose pembrolizumab (200 mg every 3 weeks) in second-line setting (KEYNOTE-139, NCT02399371) confirmed both the activity and tolerability of such anti-PD-1 agent in pre-treated MPM patients. 28 Overall, 35 MPM patients, PS = 0-1, with disease progression after 1-2 prior regimens, one of which including pemetrexed-platinum doublet, and measurable disease and were treated using pembrolizumab 200 mg intravenously q21 days with first computer tomography (CT)-scan evaluation at 9 weeks. Their median age was 68 years, while 53% were PS = 0; epithelioid histology was revealed in 77%, 12% had peritoneal while 61% of patients had received only one prior treatment. Partial response according to mRECIST was observed in 14 patients (22%), while 26 displayed stable disease (56%), providing a 63% DCR at 9 weeks.
Indeed, median PFS was 7. 2 months in PD-L1 tumor expression >1% patients, compared with 2. 9 months for PD-L1-negative patients; median OS was 17. 3 months in PD-L1positive patients versus 11. 6 months for PD-L1negative patients. Grade-3 interstitial pneumonia or pneumonitis occurred in three of the 20 PD-L1-positive patients (15%). Based on the MERIT study results, nivolumab was approved in Japan for unresectable advanced or recurrent MPM patients, having progressed upon previous chemotherapy. Results from the MPM strata of the multicenter non-randomized, open-label, and multicohort 'basket' Phase-Ib trial 'JAVELIN' (NCT01772004) were presented as a poster session at 2018 ASCO meeting. 32 This trial assessed the anti-PD-L1 fully humanized IgG1 avelumab in around 2,200 patients suffering from more than 15 cancer types.
40 onversely, 12 and five patients, respectively, exhibited more than 60% of tumor size increase, with major and rapid tumor burden progression exceeding 80% observed in a few patients (six and two, respectively). [43]  After a median 32. 5-month follow-up, median response duration was 7. 4 months in the nivolumab group vs 8. 3 months in the combination group. More strikingly, median OS was 11•9 months (95% CI: 6. 7-17. 4) and 15•9 months (95% CI: 10. 7-22. 2), in the nivolumab and nivo + ipi groups, respectively, with a 2-year OS of 25. 4%, (95% CI: 15. 5-36. 6) and of 31. 7% (95% CI: 20. 5-43. 4) for nivolumab and nivo + ipi groups, respectively. No imbalance in post-discontinuation treatments received by patients was detected between both arms. Another smaller, yet non-randomized trial ('INITIATE', NCT03048474) using the same design than the NIVOMES trial, carried-out by P.
Baas et al. , showed similar trends of treatment benefits. This trial involving 35 patients assessed the usefulness of administrating nivolumab (1 mg/kg/3 weeks vs /2 weeks as in MAPS-2) plus ipi (1 mg/kg/6 weeks) as second-or third-line treatment in MPM (85%) patients. 37 ORR and DCR at 12 weeks were 30% and 75%, respectively, with a 4. 8-month PFS, yet still immature OS data. A third single-arm Phase-II trial ('NIBIT-MESO-1'; NCT02588131) evaluated combined 1 mg/kg tremelimumab and 20 mg/kg durvalumab given in four intravenous doses every 4 weeks, which was followed by durvalumab maintenance at the same dose and schedule for nine doses, as first-or second-line treatment for unresectable malignant mesothelioma patients. 38 This trial met its primary endpoint, with 11/40 (27•5%) patients exhibiting immune-related (ir)-partial response (median DOS: 16.
With a median 28-month follow-up, median PFS was 6. 9 months (95% CI: 5•5-9•0), and 6-month PFS was 57%. The median OS was 18. 4 months (95% CI: 13. 1-24. 8); 24-month OS was 37% (95% CI: 26-52). Overall, 15% of patients experienced Grade 3-4 IRAEs, 13% experienced Grade 3-4 neutropenia, 7% Grade 3-4 anemia, with 66% of patients experiencing Grade 3-5 adverse events, including five deaths (9%) during study treatment including one tumor progression, without any death adjudicated to durvalumab. These results supported the launching of a Phase-3 trial titled 'DREAM3R'' (NCT04334759) in the first-line setting, with OS as primary endpoint, sponsored by PrECOG and the ALTG Australian group. This trial is designed to recruit 480 patients until 2024. In the meantime, the results of the IND227-IFCT1901 (NCT02784171) Phase 2-3 trial, which was initiated by the Canadian Cancer Trials Group along with the French Intergroup (IFCT) will be made available.
6% at 6 mo 6. 1 17. 3 Okada et al. 31 CTI-No. 163247) JAVELIN Second or further Anti-PD-L1 avelumab Pleural + peritoneal 1b 53 58. 5% 4. 1 10. 9 Hassan et al. 32 ETOP 9-14 PROMISE-Meso Second/ third Anti-PD-1 pembrolizumab Pleural + peritoneal 3 144 39% vs. 29% 2. 5 vs. 3. 4 10. 7 vs. 11. 7 Popat et al. 33 (NCT02991482) vs gemcitabine or vinorelbine CONFIRM (University of Second Anti-PD-1 nivolumab vs Pleural + peritoneal 3 336 (221:111) NA 3. 0 vs. 1. 8 9. 2 vs. 6. 5 Fenell et al. 34 Southampton) placebo (double (CRUK 16/022) blind) KEYNOTE-158 a Second Anti-PD1 Pleural + peritoneal 2 1350 NA NA NA Yap et al. (NCT02628067) or further pembrolizumab (total) lines 118 MPM 35DCR, disease control rate; MPM, malignant pleural mesothelioma; NA, not available; OS, overall survival; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival.
26 Meso (NCT02991482) gemcitabine or vinorelbine CONFIRM (Southampton Second Anti-PD-1 nivolumab vs UNK 3 Popat et al. 33 university) (CRUK 16/022) placebo (double blind) KEYNOTE-158 Second or Anti-PD1 pembrolizumab clone 22C3 PharmDx 2 Yap et al. (NCT02628067) further assay basket 35IHC, immunohistochemistry; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; UNK, unknown. journals. sagepub. com/home/tam.
To close the loop between scientific evidence and clinical practice, rigorous assessment and implementation of mechanical ventilation-associated interventions are key. In this issue of the Journal, Sud and colleagues (pp. 1366-1377) show clinically relevant data  (8). The authors performed a network meta-analysis of randomized trials to decipher the contribution of VT, PEEP, prone ventilation, highfrequency oscillation, and venovenous extracorporeal membrane oxygenation (VV-ECMO) on hospital mortality in moderate to severe ARDS not related to COVID-19. They enriched the network meta-analysis technique by adding an assessment of the certainty of evidence to its conventional metrics. The study included 34 trials totalizing 9,085 patients with mortality data available. The main finding was that the low VT-prone strategy was significantly better than the low VT strategy alone (relative risk, 0.
| SEARCH STRATEGY An electronic literature search was performed in January 2021 using the PubMed database (www. ncbi. nlm. nih. gov/PubMed) with the aim of identifying all peerreviewed articles without date restriction that reported occurrence of PANS in dogs. Search strategy details are presented in Appendix S1 in File S1. Exclusion criteria included articles in a non-English language, experimental or in vitro studies, reviews, editorials, letters to the editor, and studies that did not describe occurrence of PANS. Potential additional references were searched from reference lists of final PubMed selected articles. Article selection and data extraction were performed by the primary author. The electronic search identified 962 citations, of which 706 were excluded based on their title and abstract.
ACKNOWLEDGMENTS Author Contributions:  Mullins RA , DECVS: Conception, design, article selection, data extraction and assignment of level of evidence, manuscript preparation and review. All other authors provided critical and meaningful reviews of the manuscript and contributed to its scientific content. The authors would like to thank  Drs J. Brad Case, DVM, MS, DACVS  ( University of Florida, USA );  Ameet Singh, BSc, DVM, DVSc, DACVS  ( University of Guelph, Canada );  Kelley M. Thieman Mankin, DVM, MS, DACVS  ( Texas A&M University, USA ); and  Anne Kummeling, DVM, PhD ,  DECVS  ( Utrecht University, Netherlands ) for reviewing the manuscript. Open access funding provided by  IReL.
Acknowledgements We thank  Dr. Egle Conforto  from the  CCA platform of La Rochelle University  for her assistance in SEM observation. This work was financially supported by  INNOV'IA and IDCAPS  ( La Rochelle , France). Fig. 6. SEM observations (left to right: x8,000; x20,000; x100, 000 ) of spray-dried  PPI-TRAG, PPI-GAC, PPI-ALG  and  PPI-TARA  coacervates prepared at a ratio of 5:1.
There are no drastic changes for other frequencies. To determine the efficacy, the lamp voltage and current are measured. We then can have access to the mean consumed power and luminance (Figure  2 ). This allows the evaluation of the lamp's luminous flux. The lamp emission is Lambertian. The 2D luminance measurements are performed by a Rollei d30-flex luminance meter from LMK. The LMK2000 software gives a 2D mapping of the luminance as well as its cross-section. A 12 lm/W efficacy for the Planilum lamp from Saint Gobain Recherche (SGR), Paris, France, with standard conditions is obtained. Spectra measurements confirm the discrete emission of the lamp (Figure  3 ). The optical spectrum allows getting the color temperature of the light. Most visible light comes from the three phosphors. Some Infrared emissions come from the discharge itself, like the 823 and 828 nm from xenon and neon.
Figure2(right) shows the luminance measurement; all the visible lines emission are integrated. There are no drastic changes for other frequencies. To determine the efficacy, the lamp voltage and current are measured. We then can have access to the mean consumed power and luminance (Figure2). This allows the evaluation of the lamp's luminous flux. The lamp emission is Lambertian. The 2D luminance measurements are performed by a Rollei d30-flex luminance meter from LMK. The LMK2000 software gives a 2D mapping of the luminance as well as its cross-section. A 12 lm/W efficacy for the Planilum lamp from Saint Gobain Recherche (SGR), Paris, France, with standard conditions is obtained. Spectra measurements confirm the discrete emission of the lamp (Figure3). The optical spectrum allows getting the color temperature of the light.
| Data extraction and synthesis Data were extracted by one author (A. B. ) using standardized forms and then checked by another author (J. M. O. ). The characteristics of each included article included reference, study design, number of participants included, population characteristics (age, BMI, % female, and type of surgery), description of exercise intervention and comparison, outcomes, and duration of follow-up. [17] [18] [19] [20]  The findings pertaining to body weight and body composition (fat mass and lean body mass), physical fitness, habitual physical activity, health-related quality of life, and health outcomes of each included article are reported. Data from intention-to-treat (ITT) analyses were included whenever reported in included studies. In addition, conclusions made by the study authors were reported, as well as our appreciation of the author's conclusion.
| RESULTS The database search yielded 4348 articles (2858 after removing duplicates), 2793 of which were eliminated based on titles and abstracts alone (Figure  1 ). The full text was retrieved from 65 articles, and 31 met the inclusion criteria. Parent trials by Coen et al. 26  and Mundbjerg et al. 27  were each reported in four additional articles  [28] [29] [30] [31] [32] [33] [34] [35]  ; those by Castello et al. 36  and by Baillot et al. 37  were each reported in one additional article. 38, 39 One article assessed two distinct interventions. 17 Therefore, a total of 22 distinct interventions were included of which 16 were included in the meta-analyses.
11435013 , No. 11475187 , No. 11521505 , No. 11575017 , No. 11675166 , No. 11705209 ; No. 11761141009 ; No. 11975076 ; No. 12042509 ;  Key Research Program of Frontier Sciences, Chinese Academy of Sciences (CAS) , Grant No. QYZDJ-SSW-SLH011 ; the  CAS Center for Excellence in Particle Physics (CCEPP) ; the  Shanghai Pujiang Program  under Grant No. 18PJ1401000 ; the  Ministry of Education, Youth and Sports of the Czech Republic  under Contract No. LTT17020 ; the  Carl Zeiss Foundation , the  Deutsche Forschungsgemeinschaft , the  Excellence Cluster Universe , and the  VolkswagenStiftung ; the  Department of Science and Technology of India ; the  Istituto Nazionale di Fisica Nucleare of Italy; National Research Foundation (NRF)  of Korea Grant Nos. 2016R1D1A1B01010135 ,  2016R1D1A1B-02012900 ,  2018R1A2B3003643 ,  2018R1A6A1A06024970 ,  2018R1D1A1B07047294 ,  2019K1A3A7A09033840 ,  2019R1I1A3A01058933 ;  Radiation Science Research Institute, Foreign Large-size Research Facility Application Supporting  project, the  Global Science Experimental Data Hub Center  of the  Korea Institute of Science and Technology Information and KREONET/GLORIAD ; the  Polish Ministry of Science and Higher Education  and the National Science Center; the  Ministry of Science and Higher Education of the Russian Federation ,  Agreement 14.
Acknowledgments:  Marc Dubois  acknowledges  I-Site CAP2025 ,  Université Clermont Auvergne , and  Clermont Auvergne Métropole  for support via the  Académie   CAP20-25. Acknowledgments:  Marc Dubois  acknowledges  I-Site CAP2025 ,  Université Clermont Auvergne , and  Clermont Auvergne Métropole  for support via the  Académie   CAP20-25.
Search Strategy and Study Selection An online search was performed in PubMed/MEDLINE in December 2020 to identify articles reporting different techniques of fundoplication associated with LSG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed for selecting the eligible studies. The following term combination was used: (sleeve, fundoplication), (sleeve, Nissen), (sleeve, Rossetti), (sleeve, Toupet) and (sleeve, Dor). The reference list of the retrieved articles was also manually checked for relevant papers. The conference abstracts considered "gray literature", were not analyzed. No publication date or language limit was considered for our search strategy. A total of 154 records were identified by the initial search of the PubMed/MEDLINE databases. Of these, 116 papers were excluded after screening by title and abstract.
The deep ANN-based model has been used for predicting the tank-to-wheel CO 2 emissions. The correlations between the HEV design parameters has been reached. The prediction model data management has been properly performed  [34]. From the results, the model can be further efficiently used for optimal (Internal Combustion Engine) ICE-based HEV designs. In Ref. [35] , the energy management strategy (EMS) hybrid FC/UC vehicular system has been developed based on a combined wavelet transform/ANN for controlling the power distribution while operating the FC and SC during steady state and transient conditions respectively. The PEMFC parameter identification has been proposed an improved Elman ANN optimized by a hybrid optimizer based on the world cup optimization (WCO) combined to the fluid Search Optimization (FSO)  [36].
Since the analytical model, expressing FCs' characteristics was not accurate in comparison with the real system's performance. The robust and dynamic model for FCs became necessary. The authors have studied the optimized model for Proton-Exchange Membrane Fuel Cell (PEMFC) integrated into electric bicycle that consists of a 250 W FC, battery pack, DC/DC convertor, electric motor and Electric Control Unit (ECU)  [47]. Moreover, in Ref. [48] , the moth-flame optimizer (MFO) approach to improve the power extraction from the Solid Oxide Fuel Cell (SOFC) through defining the model optimal parameters. The cell model has been identified via trained ANN using experimental dataset. The results have illustrated the enhanced output power extraction using the proposed hybrid ANN-MFO technique. The authors of  [49]  have studied the multi-objectives energy management for microgrids considering random EV charging.
Lyapunov stability), simulation then until practical validation are studied. Limitations of energy resources are considered to share the energy and the minimization of hydrogen consumption are the key of our study. One limitation of this approach is that it needs a dataset for the training process -Nonlinear method Storage source supervision in terms of SOC of battery and SC to maintain the DC bus voltage -SOC of battery and SC are considered to decrease the hydrogen consumption. The stability proof is given by Lyapunov approach. -Validation by simulation Validation by the simulation of proposed methods with the existing approaches. -Stability proof Limitations here are the lack of experimental validation and the consideration of the remaining hydrogen level. [51,52] IDA-PBC þ HJB -Nonlinear method SOC of storage systems and H2 level are considered.
Conclusion In this research work, a kinematic and dynamic model for BlueROV2 was developed using dual quaternions, which allow us to calculate the position and orientation in a function without presenting singularities to difference of the use of representation by Euler's angles. On the other hand,mathematical properties of the model are obtained to facilitate the demonstration of the stability of the controllers based on the theory of dual quaternions. To validate the aforementioned, the development of three controllers is proposed: PD+G, adaptive control and robust control. In addition, a com-parison is made between controllers and it is observed which one presents a better performance, based on the graphs of the results and the data obtained from the Table  2 , where the RMSE values are shown, it is concluded that the best performance index for the tracking of trajectory in position, it is presented by the adaptive controller, and for the case of orientation it is the robust controller.
Finally, conclusions are drawn and the outlook for the future is presented. The present review is divided into four main sections. First, a synthetic database is proposed to know how the literature deals with frost issues in industrial freezing processes. In the second section, the frosting process is explained, focusing on the studies that have been carried out to examine the properties of frost and its growth under different conditions and for different applications. The third section is devoted to studies related to frost thermal and hydraulic effects. The last section is devoted to studies aimed at managing the problem of frost. At the end of each section, and by combining elements from the literature with the author's knowledge, the particularities of the deep-freezing process are pointed out.
Preliminary overview of research on industrial freezing conditions Based on the existing literature from the 1957 to 2020, a database of around 130 papers has been generated in order to categorize the studies carried out under freezing conditions and on an industrial scale compared to those carried out under other conditions (heat pump, HVAC, cryogenic, etc. ) and at other scales (laboratory, domestic, etc. ). In the framework of the objective of this review, the literature which reported frosting and defrosting research in any conditions or applied to any field was selected. Then, the appropriate literature was classified by year of publication. Next, the literature was classified by: -Type of studies: experimental or numerical/theoretical; -Type of geometry: simple geometry (flat plate, cylinder, parallel plates, vertical plate) or complex geometry (finned-tube, microchannel, etc.
Study Population The enrolled population was composed of headache sufferers aged C 18 years, who lived in the USA and self-reported experiencing 5--14 days with headache per month on average. Participants were required to own and encouraged to wear a Fitbit activity tracker (any model) daily for the duration of the study. Participants were excluded if they had any other pre-existing neurological condition, such as epilepsy, had a sleep disorder, such as narcolepsy or insomnia, or had a lifestyle that led to irregular or atypical circadian patterns (e. g. , overnight shift work). Analysis Population 1 included all participants with daily surveys (no more than 7 consecutive days of missing surveys) and activity trackers: dense data (no more than 7 consecutive invalid days of tracker data determined by \ 10 h of wear time based on steps data).
Data Sources and Variables Self-reported data were collected through baseline and daily surveys completed via email, and activity data were collected at the minute level using Fitbit activity trackers throughout the study period. At baseline, all participants completed a headache-specific QoL Migraine Disability Assessment (MIDAS)  [4]  and answered questions on demographics, medical history, headache type, average pain intensity, medication use, and general lifestyle. Participants also responded to questions about their headache symptoms, which were used to classify their headache types into migraine, tension-type headache (TTH), or cluster headache, based on questions specifically adapted from the International Classification of Headache Disorders 3 (ICHD-3)  [5]. Daily surveys assessed the occurrence of headache and QoL on days with headache (perceived impact of headache on daily life and overall well-being [self-rated health]) each day throughout the study.
Statistical Analysis Results were summarized using descriptive statistics: per-participant percentage of missing data and distributional features of primary and secondary evaluation variables (median, mean, standard deviation, etc. ), as deemed appropriate. All statistical analyses were performed at the 5% significance level using two-sided tests or two-sided 95% confidence intervals (CI); P values were adjusted for the false discovery rate (FDR) via the Benjamini-Hochberg procedure. A sample size of approximately 500 participants was estimated as required to identify significant effects across activity tracker-based endpoints, accounting for FDR correction using the error rate of 5% and power of 80% and assuming that 50% of the activity features will yield an 18% difference between days with and without headache for each feature.
Missing data were reported and evaluated for randomness using heatmaps and exploratory analyses of associations with baseline participant-level characteristics. Activity tracker data was evaluated for meeting quality standards  [6, 7]. Missing values and extreme values determined to be outliers (below the 0. 05th percentile or above 0. 95th percentile) were excluded from analysis or truncated. All analyses were conducted in R v. 3. 6. 0 or higher.
Study Participation Of the 2157 potential participants who were screened, 509 met the eligibility criteria, completed baseline assessments, connected their Fitbit to the study platform and were enrolled in the study (Fig. 1a ). Of these, 350 participants had dense survey and activity data and were included in Analysis Population 1. A total of 283 participants had dense survey and heart rate data and were included in Analysis Population 2 (Fig. 1a ).